A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA)

Studies seeking participants A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA)

Posted: November 26, 2021

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson’s Disease (PD) who are on stable symptomatic PD medication.

You may be eligible if the following apply:
• Diagnosis of PD plus one of the other cardinal signs of PD (resting tremor, rigidity), without any other known or suspected cause of parkinsonism
• On symptomatic PD medication for at least 6 months
• A diagnosis of PD for at least 6 months to maximum 3 years at screening

Contact information

Name: Justine Reaume
Email: jreaume@memorydisorders.ca
Phone: 416-386-9761 extension 364

Share this:

Stay current on Parkinson’s news in Canada

Subscribe to get news and important updates about how, together, we're improving the lives of people living with Parkinson's. Stay up to date through email or social media.

Leave this field empty:

Please enter your basic information

First Name *

Last Name *

Email *

YES, by checking this box and providing my contact information herein, I consent to be contacted by and receive news, updates and information from Parkinson Canada.

Postal *